Ángel A. Rivera

2.2k citations

46 papers · 1.7k indexed · h-index 24

Impact in

Genetics top 2%
- Virus-based gene therapy research
- Mesenchymal stem cell research
Oncology top 5%
- CAR-T cell therapy research

Papers in

Genetics 33
- Virus-based gene therapy research 33
- Mesenchymal stem cell research 2
Oncology 22
- CAR-T cell therapy research 17

Co-authors: David T. Curiel J. Michael Mathis Ilya V. Ulasov Dirk M. Nettelbeck Maciej S. Lesniak Zeng B. Zhu Matthew A. Tyler Minghui Wang
Journals: Cancer Biology & Therapy (4 papers)Cancer Gene Therapy (3 papers)Human Gene Therapy (2 papers)International Journal of Cancer (2 papers)Virology (2 papers)
Partner nations: United States Germany France

In The Last Decade

Ángel A. Rivera

45 papers receiving 1.7k citations

Peers

Countries citing papers authored by Ángel A. Rivera

Since Specialization

Citations

This map shows the geographic impact of Ángel A. Rivera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ángel A. Rivera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ángel A. Rivera more than expected).

Fields of papers citing papers by Ángel A. Rivera

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ángel A. Rivera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ángel A. Rivera. The network helps show where Ángel A. Rivera may publish in the future.

Co-authors

The 25 scholars most cited alongside Ángel A. Rivera, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ángel A. Rivera Line = papers co-authored together Ángel A. Rivera links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	F5‐Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV‐short production Journal of Thrombosis and Haemostasis ·Karen L. Zimowski, Teodolinda Petrillo, Michelle Ho, Julie R Wechsler, Jordan E Shields, Gabriela Denning, Navdeep Jhita, Ángel A. Rivera, Miguel A. Escobar, Christine L. Kempton, Rodney M. Camire, Christopher B. Doering	2021	14
2	Factor V Atlanta: A Novel Mutation in the F5 Gene Reveals Potential New Cis-Acting Elements Involved in Regulating FV-Short and TFPI Levels Blood ·Karen L. Zimowski, Michelle Ho, Jordan E Shields, Gabriela Denning, Teodolinda Petrillo, Navdeep Jhita, Ángel A. Rivera, Miguel A. Escobar, Christine L. Kempton, Christopher B. Doering, Rodney M. Camire	2017	5
3	CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter PubMed ·Shilpa Bhatia, Samia M. O’Bryan, Ángel A. Rivera, David T. Curiel, J. Michael Mathis	2016	13
4	Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model Laboratory Investigation ·James J. Cody, Ángel A. Rivera, Gray R. Lyons, Sherry W. Yang, Minghui Wang, Jason W. Ashley, Sreelatha Meleth, Xu Feng, Gene P. Siegal, Joanne T. Douglas	2013	3
5	Increased Plasma Chymase Concentration and Mast Cell Chymase Expression in Venous Neointimal Lesions of Patients with CKD and ESRD Seminars in Dialysis ·Haimanot Wasse, Ángel A. Rivera, Rong Huang, Deborah E. Martinson, Qi Long, William McKinnon, Nawazish Naqvi, Ahsan Husain	2011	21
6	Evaluation of E1A double mutant oncolytic adenovectors in anti‐glioma gene therapy Journal of Medical Virology ·Ilya V. Ulasov, Matthew A. Tyler, Ángel A. Rivera, Dirk M. Nettlebeck, Joanne T. Douglas, Maciej S. Lesniak	2008	16
7	Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach Virology Journal ·Qiana L. Matthews, PingAr Yang, Qi Wu, Н. В. Белоусова, Ángel A. Rivera, Mariam A. Stoff‐Khalili, Reinhard Waehler, Hui‐Chen Hsu, Zan Li, Jing Li, John D. Mountz, Hongju Wu, David T. Curiel	2008	38
8	Promotion of incisional wound repair by human mesenchymal stem cell transplantation Experimental Dermatology ·Alexander Stoff, Ángel A. Rivera, N. Sanjib Banerjee, Steven T. Moore, T. Michael Numnum, A. Espinosa de los Monteros, Dirk F. Richter, Gene P. Siegal, Louise T. Chow, Dale S. Feldman, Luis O. Vásconez, J. Michael Mathis, Mariam A. Stoff‐Khalili, David T. Curiel	2008	101
9	Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control Breast Cancer Research and Treatment ·Mariam A. Stoff‐Khalili, Ángel A. Rivera, Ana Nedeljkovic-Kurepa, Arrigo DeBenedetti, Xiaolin Li, Yoshinobu Odaka, Jagat P. Podduturi, Don A. Sibley, Gene P. Siegal, Alexander Stoff, Scott Young, Zheng Bin Zhu, David T. Curiel, J. Michael Mathis	2007	29
10	Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma Breast Cancer Research and Treatment ·Mariam A. Stoff‐Khalili, Ángel A. Rivera, J. Michael Mathis, N. Sanjib Banerjee, Amanda S. Moon, Angela R. Hess, Rodney P. Rocconi, T. Michael Numnum, Maaike Everts, Louise T. Chow, Joanne T. Douglas, Gene P. Siegal, Zeng B. Zhu, Hans Bender, Peter Dall, Alexander Stoff, L Pereboeva, David T. Curiel	2007	157
11	Effect of adenoviral mediated overexpression of fibromodulin on human dermal fibroblasts and scar formation in full-thickness incisional wounds Journal of Molecular Medicine ·Alexander Stoff, Ángel A. Rivera, J. Michael Mathis, Steven T. Moore, N. Sanjib Banerjee, Maaike Everts, A. Espinosa de los Monteros, Zdeněk Novák, Luis O. Vásconez, Thomas R. Broker, Dirk F. Richter, Dale S. Feldman, Gene P. Siegal, Mariam A. Stoff‐Khalili, David T. Curiel	2007	42
12	Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo Cancer Biology & Therapy ·Myung‐Hee Kim, Thomas M. Bodenstine, L A Sumerel, Ángel A. Rivera, Andrew H. Baker, Joanne T. Douglas	2006	8
13	Targeting lung cancer using an infectivity enhanced CXCR4-CRAd Lung Cancer ·Zeng B. Zhu, Ángel A. Rivera, Sharmila Makhija, Baogen Lu, Minghui Wang, Miiru Izumi, Robert J. Cerfolio, Mariam A. Stoff‐Khalili, Fen Zhou, Koichi Takayama, Gene P. Siegal, David T. Curiel	2006	10
14	Icodextrin enhances survival in an intraperitoneal ovarian cancer murine model utilizing gene therapy Gynecologic Oncology ·Rodney P. Rocconi, Michael T. Numnum, Zeng B. Zhu, Baogen Lu, Minghui Wang, Ángel A. Rivera, Mariam A. Stoff‐Khalili, Ronald D. Alvarez, David T. Curiel, Sharmila Makhija	2006	2
15	Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system Breast Cancer Research ·Mariam A. Stoff‐Khalili, Alexander Stoff, Ángel A. Rivera, N. Sanjib Banerjee, Maaike Everts, Scott Young, Gene P. Siegal, Dirk F. Richter, Minghui Wang, Peter Dall, J. Michael Mathis, Zeng B. Zhu, David T. Curiel	2005	29
16	Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures Molecular Cancer Therapeutics ·N. Sanjib Banerjee, Ángel A. Rivera, Minghui Wang, Louise T. Chow, Thomas R. Broker, David T. Curiel, Dirk M. Nettelbeck	2004	46
17	Transcriptional targeting of tumors with a novel tumor-specific survivin promoter Cancer Gene Therapy ·Zeng B. Zhu, Sharmila Makhija, Baogen Lu, Minghui Wang, Lioudmila Kaliberova, Bin Liu, Ángel A. Rivera, Dirk M. Nettelbeck, Parameshwar J. Mahasreshti, Charles A. Leath, Shannon Barker, M Yamaoto, Fengzhi Li, Ronald D. Alvarez, David T. Curiel	2004	86
18	Enhanced Adenovirus Infection of Melanoma Cells by Fiber-Modification: Incorporation of RGD Peptide or Ad5/3 Chimerism Cancer Biology & Therapy ·Andrea L. Volk, Ángel A. Rivera, Anna Kanerva, Gerd Bauerschmitz, Igor P. Dmitriev, Dirk M. Nettelbeck, David T. Curiel	2003	59
19	β-phosphorothioate analogs of nucleotide sugars are resistant to hydrolytic degradation and utilized efficiently by glycosyltransferases Analytical Biochemistry ·Richard B. Marchase, Maureen F. Burkart, Ángel A. Rivera, Benjamin L. Clarke, Barry D. Shur, Gary T. Overmeyer, D.R.D. Shaw	1991	3
20	The β-phosphoro[35S]thioate analogue of UDP-Glc is efficiently utilized by the glucose phosphotransferase and is relatively resistant to hydrolytic degradation Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology ·Richard B. Marchase, Ann M. Saunders, Ángel A. Rivera, Jennifer M. Cook	1987	13

About Ángel A. Rivera

Ángel A. Rivera is a scholar working on Genetics, Oncology, Molecular Biology, Rehabilitation and Immunology, having authored 46 papers that have together received 1.7k indexed citations. Recurring topics across this work include Virus-based gene therapy research (33 papers), CAR-T cell therapy research (17 papers), Viral Infectious Diseases and Gene Expression in Insects (17 papers), RNA Interference and Gene Delivery (14 papers), Immunotherapy and Immune Responses (3 papers), Blood Coagulation and Thrombosis Mechanisms (3 papers), Hemophilia Treatment and Research (2 papers) and Mesenchymal stem cell research (2 papers). The work is most often cited by research in Genetics (1.1k citations), Genetics (293 citations), Oncology (737 citations), Biotechnology (214 citations) and Rehabilitation (115 citations). Ángel A. Rivera has collaborated with scholars based in United States, Germany and France. Frequent co-authors include David T. Curiel, J. Michael Mathis, Ilya V. Ulasov, Dirk M. Nettelbeck, Maciej S. Lesniak, Zeng B. Zhu, Matthew A. Tyler, Minghui Wang, Gene P. Siegal and Adam M. Sonabend. Their work appears in journals such as Cancer Biology & Therapy, Cancer Gene Therapy, Human Gene Therapy, International Journal of Cancer and Virology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact